(Q33411548)

English

A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer

scientific article

Statements

A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer (English)
Bradley G Somer
Begoña Mellado
José Manuel Cervera Grau
Daniel Castellano
Christoph Reuter
Michael Stöckle
Jörn Kamradt
Joanna Pikiel
Ignacio Durán
Steffen Wedel
Sophie Callies
Valérie André
Jacqueline Brown
Michael Lahn
Bernhard Heinrich
6 November 2013

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit